Aimmune Therapeutics CEO Jayson Dallas receives $9.2M in 2018
Aimmune Therapeutics reports 2018 executive compensation
By ExecPay News
Published: April 10, 2019
Aimmune Therapeutics reported fiscal year 2018 executive compensation information on April 10, 2019.
In 2018, six executives at Aimmune Therapeutics received on average a compensation package of $3.5M, a 25% increase compared to previous year.
Average pay of disclosed executives at Aimmune Therapeutics
Jayson D.A. Dallas, Chief Executive Officer, received $9.2M in total. 73% of Dallas' compensation, or $6.8M, was in option awards. Dallas also received $337K in non-equity incentive plan, $288K in salary, as well as $1.8M in stock awards.
Douglas T. Sheehy, General Counsel, received a compensation package of $3.2M, which increased by 87% compared to previous year. 49% of the compensation package, or $1.6M, was in option awards.
Daniel C. Adelman, Chief Medical Officer, earned $2.1M in 2018, a 22% increase compared to previous year.
Eric H. Bjerkholt, Chief Financial Officer, received $2.1M in 2018, which decreases by 45% compared to 2017.
Stephen G. Dilly, Chief Executive Officer, earned $2M in 2018, a 71% decrease compared to previous year.
Susan E. Barrowcliffe, General Manager, Europe, received $2M in 2018.
Related executives
Jayson Dallas
Aimmune Therapeutics
Chief Executive Officer
Stephen Dilly
Aimmune Therapeutics
Chief Executive Officer
Eric Bjerkholt
Aimmune Therapeutics
Chief Financial Officer
Daniel Adelman
Aimmune Therapeutics
Chief Medical Officer
Douglas Sheehy
Aimmune Therapeutics
General Counsel
Susan Barrowcliffe
Aimmune Therapeutics
General Manager, Europe
You may also like
Source: SEC filing on April 10, 2019.